On the stock market since 2009, it operates in the world of health and science. It has 93 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $44.5M a year. A small number, but proof the product has real buyers.
There is $11.4M in the vault; even if every debt were paid off, $1.3M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
A loss of $2.8M against $44.5M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 36/100.
On our five-subject report card, CPIX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CPIX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.